PT - JOURNAL ARTICLE AU - Jamali, Farzaneh AU - Shahrami, Bita AU - Mojtahedzadeh, Amirmahdi AU - Najmeddin, Farhad AU - Arabzadeh, Amir Ahmad AU - Hadadi, Azar AU - Sharifzadeh, Mohammad AU - Mojtahedzadeh, Mojtaba TI - Changes of LipoxinA<sub>4</sub> Levels Following Early Hospital Management of Patients with Non-Severe COVID-19: A Pilot Study AID - 10.1101/2022.04.18.22273880 DP - 2022 Jan 01 TA - medRxiv PG - 2022.04.18.22273880 4099 - http://medrxiv.org/content/early/2022/04/20/2022.04.18.22273880.short 4100 - http://medrxiv.org/content/early/2022/04/20/2022.04.18.22273880.full AB - LipoxinA4 (LXA4) is an anti-inflammatory biomarker participating in the active process of inflammation resolution, which is suggested to be effective on infectious and inflammatory diseases like COVID-19. In this study, we hypothesized that LXA4 levels may increase following COVID-19 treatment and are even more accurate than commonly used inflammatory markers such as erythrocyte sedimentation rate (ESR), c-reactive protein (CRP), and ferritin. To test this hypothesis, a pilot study was conducted with 31 adult hospitalized patients with non-severe COVID-19. LXA4 levels were measured at the baseline and 48-72 hours later. Accordingly, ESR and CRP levels were collected on the first day of hospitalization. Moreover, the maximum serum ferritin levels were collected during the five days. LXA4 levels significantly increased at 48-72 hours compared to the baseline. ESR, CRP, and ferritin levels were positively correlated with the increased LXA4. In contrast, aging was shown to negatively correlate with the increased LXA4 levels. LXA4 may be known as a valuable marker to assess the treatment response among non-elderly patients with non-severe COVID-19. Furthermore, LXA4 could be considered as a potential treatment option under inflammatory conditions. Further studies are necessary to clarify LXA4 role in COVID-19 pathogenesis, as well as the balance between such pro-resolving mediators and inflammatory parameters.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the Tehran University of Medical Sciences. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the ethics committee of Sina Hospital and Tehran University of Medical Sciences (TUMS) (IR.TUMS.MEDICINE.REC.1399.755).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript